Escherichia coli
fidaxomicin
strain
WO153
isolate
NA
host
NA
isolation_source
NA
collection_date
2016/2018
geo_loc_name
NA
altitude
NA
biomaterial_provider
NA
culture_collection
NA
depth
NA
env_broad_scale
NA
genotype
NA
host_tissue_sampled
NA
identified_by
NA
lab_host
NA
lat_lon
NA
mating_type
NA
passage_history
NA
samp_size
NA
serotype
NA
serovar
NA
specimen_voucher
NA
temp
NA
sample_type
cell culture
id_espinoza-et-al
fidaxomicin|dmso-10|1|2|10.0|38|s38
run
10.0
id_jira
SOLEXASEQ-1137
id_orourke-et-al
R10_Fidaxomicin_BR2
id_sequencing-number
S38
id_barcode-number
38
biological_replicate
2
sample-category
pure_compound
sample-category_encoding
1
cpd_local
fidaxomicin
cpd_universal
fidaxomicin
ctrl_local
dmso-10
ctrl_universal
dmso
og_moa
rna-polymerase
moa
rna-polymerase
moa_encoding
2
moa_color
#db57d3
neu_sub-moa
rna-synthesis
neu_sub-moa_description
inhibits RNA polymerase, particularly DNA strand separation
neu_sub-moa_encoding
2.0
gene_target_description
With the 2011 FDA approval of Lpm (fidaxomicin/Dificid) for treatment of C. difficile-associated diarrhea, the RNAP switch region now is a proved target for antibacterial drug discovery and antibacterial therapy.”- Srivastava et al. 2011
ORourke_et_al
True
Espinoza_et_al
True
BioSampleModel
Microbe, viral or environmental